Tumour treating fields (TTFields) for the treatment of glioblastoma Tumor treating fields (TTFields) for patients with glioblastoma * Homepage * Main navigation * Content area * Sitemap * SearchThe Federal Administration in treecrumb format * The federal Council * The federal Council admin.ch * FCh: Federal Chancellery * FDFA: Federal Department of Foreign Affairs
Bevacizumab (Abevmy) - Colorectal Cancer, Non-Small Cell Lung Cancer, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer, Glioblastoma Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel
Somatic gene testing for the diagnosis of glioma, including glioblastoma 1 Public Summary Document Application No. 1709 Somatic gene testing for the diagnosis of glioma, including glioblastoma Applicant: Royal College of Pathologists of Australasia Date of MSAC consideration: MSAC 84th Meeting, 31 March - 1 April 2022 1. Purpose of application An application requesting Medicare Benefits Schedule (MBS) listing of a somatic gene panel test for the diagnosis of glioma, including glioblastoma, was received from the Royal College of Pathologists of Australasia (RCPA) by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC
Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma A Singapore Government Agency WebsiteHomeHealthcare ProfessionalsACE Horizon ScanningOptune for the Treatment of Newly Diagnosed and Recurrent GlioblastomaPublished on 22 May 2023Last Updated on 22 May 2023A-A+This Horizon Scanning Brief provides an assessment of Optune for the treatment of patients with newly diagnosed or recurrent glioblastoma. Download the PDF below to access the Horizon Scanning Brief.Optune for the Treatment of Newly Diagnosed and Recurrent GlioblastomaAgency for Care Effectiveness (ACE)Who We AreOrganisational StructureOur Council and Expert Panels Committees We ServeCareers at ACEOur ImpactHealthcare ProfessionalsACE Clinical Guidances (ACGs)ACE CUESACE Technology GuidancesACE Horizon
Summary - Optune for the treatment of adult patients with newly diagnosed glioblastoma i Optune™ for the treatment of adult patients with newly diagnosed glioblastoma English summary Une production de l’Institut national d’excellence en santé et en services sociaux (INESSS) SEPTEMBER 2023 1 SUMMARY Optune™ for the treatment of adult patients with newly diagnosed glioblastoma Mandate L’Institut national d’excellence en santé et en services sociaux (INESSS) was mandated by the Bureau de l'innovation to assess the value of OptuneTM technology and the relevance of its coverage by the public plan as a treatment device for adult patients with newly diagnosed glioblastoma with and after standard temozolomide maintenance chemotherapy. Description For the requested indication, the device requires
Bevacizuma (Bambevi) - Metastatic Colorectal Cancer, Metastatic or Recurrent Non-Small Cell Lung Cancer, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer or Glioblastoma Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch
ESTRO/EANO recommendation on reirradiation of glioblastoma www.thegreenjournal.com Verify you are human by completing the action below. www.thegreenjournal.com needs to review the security of your connection before proceeding.Ray ID: 905155c1795a0691Performance & security by Cloudflare
Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma. Adavosertib is an oral small molecular inhibitor of Wee1. The Adult Brain Tumor Consortium performed a phase I study of adavosertib, radiation (RT) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) as well as a surgical window
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel the results for each arm and examine the feasibility and conduct of the adaptive platform design. Patients with newly diagnosed O-methylguanine-DNA methyltransferase-unmethylated glioblastoma were eligible if they had tumor genotyping to identify prespecified biomarker subpopulations of dominant glioblastoma signaling pathways (EGFR, phosphatidylinositol 3-kinase, and CDK). Initial random assignment was 1:1
Cerebral blood flow and histological analysis for the accurate differentiation of infiltrating tumor and vasogenic edema in glioblastoma. Glioblastoma is characterized by neovascularization and diffuse infiltration into the adjacent tissue. T2*-based dynamic susceptibility contrast (DSC) MR perfusion images provide useful measurements of the biomarkers associated with tumor perfusion. This study aimed to distinguish infiltrating tumors from vasogenic edema in glioblastomas using DSC-MR perfusion images. Data were retrospectively collected from 48 patients with primary IDH-wild-type glioblastoma and 24 patients with meningiomas (Edemas-M). First, we attempted histological verification of cell density, Ki-67 index, and microvessel areas to distinguish between non-contrast-enhancing tumors (NETs
Deciphering the dose-dependent effects of thymoquinone on cellular proliferation and transcriptomic changes in A172 glioblastoma cells. Glioblastoma multiforme (GBM), the most prevalent primary malignant brain tumor in adults, exhibits a dismal 6.9% five-year survival rate post-diagnosis. Thymoquinone (TQ), the most abundant bioactive compound in Nigella sativa, has been extensively researched for its anticancer properties across various human cancers. However, its specific anti-cancer mechanisms and pathways in glioblastoma remain to be completely elucidated. In this study, we assessed the impact of different TQ concentrations on the viability of A172 cells using WST-8 and Toluidine blue assays, followed by RNA sequencing (RNA-Seq) to identify differentially expressed genes (DEGs). We
Identification and validation of TSPAN13 as a novel temozolomide resistance-related gene prognostic biomarker in glioblastoma. Glioblastoma (GBM) is the most lethal primary tumor of the central nervous system, with its resistance to treatment posing significant challenges. This study aims to develop a comprehensive prognostic model to identify biomarkers associated with temozolomide (TMZ
Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment. Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) and the DNA-alkylating agent temozolomide (TMZ
Cuproptosis-related lncRNAs and genes: Potential markers for glioblastoma prognosis and treatment. Despite the availability of various treatment options, glioblastoma (GBM) remains an extremely aggressive form of glioma with a poor prognosis. In recent studies, regulatory cell death (RCD) has been identified as an effective mechanism to suppress glioma. Cuproptosis, caused by intracellular copper
Identification of distinct profiles of glioblastoma through the immunocapture of extracellular vesicles from patient plasma. Glioblastoma (GBM), a primary brain tumor, exhibits intratumoral heterogeneity and dynamic spatial-temporal changes. GBM-derived extracellular vesicles (EVs), reflecting tumor characteristics, present potential as liquid-biopsy markers for early diagnosis and monitoring
ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma www.thegreenjournal.comChecking if the site connection is securewww.thegreenjournal.com needs to review the security of your connection before proceeding.Ray ID: 7c9a8d11daa5753dPerformance & security by Cloudflare
Tumour-treating fields in addition to current standard therapy for glioblastoma as first-line treatment 1 Translation of Chapters 1 to 6 of the rapid report N18-02 Tumortherapiefelder zusätzlich zur derzeitigen Standardbehandlung beim Glioblastom als Erstlinientherapie (Version 1.1; Status: 12 July 2019 [German original], 18 October 2019 [English translation]). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N18-02 Tumour-treating fields in addition to current standard therapy for glioblastoma as first-line treatment1 Extract
Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm. Glioblastoma (GBM) is one of the most aggressive and lethal human cancers. Intra-tumoral genetic heterogeneity poses a significant challenge for treatment. Biopsy is invasive, which motivates the development of non-invasive, MRI-based machine
Gene expression analysis suggests immunosuppressive roles of endolysosomes in glioblastoma. Targeting endolysosomes is a strategy extensively pursued for treating cancers, including glioblastomas (GBMs), on the basis that the intact function of these subcellular organelles is key to tumor cell autophagy and survival. Through gene expression analyses and cell type abundance estimation in GBMs, we
Comprehensive somatic mutational analysis in glioblastoma: Implications for precision medicine approaches. Glioblastoma multiforme (GBM), a malignant neoplasm originating from glial cells, remains challenging to treat despite the current standard treatment approach that involves maximal safe surgical resection, radiotherapy, and adjuvant temozolomide chemotherapy. This underscores the critical